Skip to main content

Table 2 Diagnostic performance of individual and combined models in detecting Aβ-PET positivity at Youden’s cutoff

From: Plasma Aβ42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study

 

Sensitivity

Specificity

PPV

NPV

LR+

LR−

Whole population (N = 59)

 TP42/40

0.778

0.875

0.732

0.900

6.22

0.25

 Age+APOE4+Clinical Group

0.944

0.805

0.680

0.945

4.84

0.07

 TP42/40+Age+APOE4+Clinical Group

0.944

0.925

0.847

0.974

12.59

0.06

 AD-Conv score

1.000

0.675

0.706

1.000

3.08

0.00

 AdjustedTP42/40+AD-Conv score

1.000

0.923

0.851

1.000

13.00

0.00

Only CN (N = 39)

 TP42/40

1.000

0.886

0.500

1.000

8.75

0.00

 Age+APOE4

0.750

0.943

0.600

0.971

12.12

0.26

 TP42/40+Age+APOE4

1.000

1.000

1.000

1.000

0.00

 AD-Conv score

1.000

0.765

0.327

1.000

4.25

0.00

 AdjustedTP42/40+AD-Conv score

1.000

1.000

1.000

1.000

0.00

Only a-MCI (N = 20)

 TP42/40

0.714

1.000

1.000

0.653

0.29

 Age+APOE4

0.357

0.833

0.799

0.411

2.14

0.77

 TP42/40+Age+APOE4

0.643

1.000

1.000

0.601

0.36

 AD-Conv score

0.846

0.500

0.759

0.636

1.70

0.31

 AdjustedTP42/40+AD-Conv score

0.615

1.000

1.000

0.583

0.38

  1. Cases in which LR+ was not quantifiable were presented as –. Prevalence considered for each group calculation was corresponding to the present cohort: 30.5% in the whole population, 10.25% in the CN group, and 65% in the a-MCI group. PET PPV-positive predictive value, NPV negative predictive value, LR+ positive likelihood ratio, LR− negative likelihood ratio